For the Inventor, By the Inventor

Enter assignee name

Zora Biosciences Oy

USPTO Granted Patents = 26

CIPO Patents = 10

EPO Patents = 12

Forward Citations = 18

Loading Chart...

Loading Chart...

19 inventors (with patents filed for the assignee):

Reijo Laaksonen (25 out of 25 patents)

Reini Hurme (18 out of 18 patents)

Kim Ekroos (17 out of 17 patents)

4. Riikka Katainen (15 out of 15 patents)

5. Kirill Tarasov (5 out of 5 patents)

6. Minna Jänis (5 out of 5 patents)

7. Mika Hilvo (4 out of 4 patents)

8. Riika Katainen (2 out of 2 patents)

9. Virve Vaeisaenen (1 out of 1 patent)

10. Matej Oresic (1 out of 3 patents)

11. Terho Lehtimäki (1 out of 1 patent)

12. Hannu Päivä (1 out of 1 patent)

13. Jonathan Shaw (1 out of 1 patent)

14. Dianna Magliano (1 out of 1 patent)

15. Kevin Huynh (1 out of 1 patent)

26 patents: Sort by Forward Citations

1. 12399188 - Biomarkers for cardiovascular events (2025-08-26),

2. 12313634 - Methods for prediction and early detection of diabetes (2025-05-27),

3. 12270816 - Lipidomic biomarkers for identification of high-risk coronary artery disease patients (2025-04-08),

4. 12025623 - Lipidomic biomarkers for atherosclerosis and cardiovascular disease (2024-07-02),

5. 11940453 - Ceramides and their use in diagnosing CVD (2024-03-26),

6. 11474116 - Ceramides and their use in diagnosing CVD (2022-10-18),

7. 10955427 - Lipidomic biomarkers for identification of high-risk coronary artery disease patients (2021-03-23),

8. 10551394 - Lipidomic biomarkers for atherosclerosis and cardiovascular disease (2020-02-04),

9. 10534001 - Methods for detecting ovarian cancer (2020-01-14),

10. 10261101 - Lipidomic biomarkers for identification of high-risk coronary artery disease patients (2019-04-16),

11. 10197582 - Ceramides and their use in diagnosing CVD (2019-02-05),

12. 10184932 - Use of ceramides and LPLs in diagnosing CVD (2019-01-22),

13. 9863965 - Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment (2018-01-09),

14. 9857386 - Lipidomic biomarkers for atherosclerosis and cardiovascular disease (2018-01-02),

15. 9841431 - Lipidomic biomarkers for identification of high-risk coronary artery disease patients (2017-12-12),

ZORA BIOSCIENCES OY is a biotechnology company that specializes in developing and providing innovative solutions for personalized medicine. They focus on biomarker discovery, clinical diagnostics, and drug development. With a strong commitment to research and development, ZORA BIOSCIENCES aims to improve patient outcomes by offering advanced diagnostic tests and targeted therapeutic approaches. Visit their website to learn more about their breakthrough technologies and services.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

26 Patents

#33 in Espoo

#132 in Finland

#24,051 in the World

Zora Biosciences Oy

Forward Citations = 18

19 inventors:

Reijo Laaksonen (25 out of 25 patents)

Reini Hurme (18 out of 18 patents)

Kim Ekroos (17 out of 17 patents)

4. Riikka Katainen (15 out of 15 patents)

5. Kirill Tarasov (5 out of 5 patents)

Please report any incorrect information to support@idiyas.com

Loading…